帕博利珠单抗在非小细胞肺癌治疗中的研究进展  

Research progress of pabolizumab in the treatment of non-small cell lung cancer

作　　者：韩强 郑纪红 宋忠全 滕晓童 谭薇[2] Han Qiang;Zheng Jihong;Song Zhongquan;Teng Xiaotong;Tan Wei(Clinical Medical College of Weifang Medical University,Weifang 261053,China;Department of Respiratory and Critical Care Medicine,Weifang People's Hospital,Weifang 261041,China)

机构地区：[1]潍坊医学院临床医学院,山东潍坊261053 [2]潍坊市人民医院呼吸与危重症医学科,山东潍坊261041

出　　处：《国际免疫学杂志》2022年第1期90-95,共6页International Journal of Immunology

摘　　要：肺癌日益成为严重危害人们健康的隐患,非小细胞肺癌(non-small cell lung cancer,NSCLC)具有患病人数多,生存期短,生活质量不佳,5年生存率低的特点。近几年分子靶向治疗对抑制肿瘤的进展起一定帮助,但预后效果有限。肿瘤细胞通过细胞程序性死亡受体-1/细胞程序性死亡配体-1(programmed cell death receptor-1/programmed cell death ligand 1,PD-1/PD-L1)相互作用使免疫细胞的监督弱化。免疫检查点抑制剂(immune checkpoint inhibitor,ICIs)通过阻断PD-1/PD-L1相互作用的条件而发生抗肿瘤作用。作为一种抗PD1抗体的单克隆免疫球蛋白(immunoglobulin,Ig)G4抗体—帕博利珠单抗,已经被批准和化疗联合一线治疗晚期NSCLC。文章针对帕博利珠单抗的作用机制、体内药学特性评价、单药治疗、联合治疗、不良反应最新进展进行综述。Lung cancer has increasingly become a hidden danger that seriously endangers people’s health.Non-small cell lung cancer(NSCLC)has the characteristics of large number of patients,short survival period,poor quality of life,and less than 5-years survival rate.In recent years,molecular targeted therapy has helped to inhibit the progress of tumor,but the prognostic effect is limited.Tumor cells weaken the supervision of immune cells through the interaction of programmed cell death receptor-1/programmed cell death ligand-1(PD-1/PD-L1).Immune checkpoint inhibitor(ICIs)has antitumor effect by blocking the conditions of PD-1/PD-L1 interaction.Pembrolizumab,a monoclonal immunoglobulin(Ig)G4 antibody against PD1 antibody,has been approved to be combined with chemotherapy for the first-line treatment of advanced NSCLC.This paper reviews the latest progress in the mechanism of action of pembrolizumab,evaluation of in vivo pharmaceutical properties,monotherapy,combination therapy,adverse effects and the latest progress of the reaction.

关 键 词：非小细胞肺癌 免疫检查点抑制剂 帕博利珠单抗 

分 类 号：R734.2[医药卫生—肿瘤]